Literature DB >> 10441509

A novel vaccine delivery system using immunopotentiating fusogenic liposomes.

A Hayashi1, T Nakanishi, J Kunisawa, M Kondoh, S Imazu, Y Tsutsumi, K Tanaka, H Fujiwara, T Hamaoka, T Mayumi.   

Abstract

We previously reported the preparation and characterization of fusogenic liposomes (FLs), which have two highly immunogenic glycoproteins of the Sendai virus on their surface. In this report, we investigated the capacity of FLs to enhance antigen-specific humoral immunity in mice. FLs function as a lymphocyte mitogen with high immunogenicity consistent with viral envelope proteins. Markedly increased levels of anti-ovalbumin (OVA) antibody were detected in serum from mice immunized with OVA encapsulated in FLs compared to sera from mice immunized with free OVA or OVA encapsulated in plain liposomes. An anti-OVA antibody response was not observed in mice immunized with OVA simply mixed with empty FLs. These results indicate that FLs function as a novel immunoadjuvant in inducing antigen-specific antibody production. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441509     DOI: 10.1006/bbrc.1999.1044

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Novel mucosal insulin delivery systems based on fusogenic liposomes.

Authors:  Takahiro Goto; Mariko Morishita; Ken Nishimura; Mahito Nakanishi; Atsushi Kato; Jumpei Ehara; Kozo Takayama
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

3.  Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens.

Authors:  N Okada; M Tsujino; Y Hagiwara; A Tada; Y Tamura; K Mori; T Saito; S Nakagawa; T Mayumi; T Fujita; A Yamamoto
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.